- Trial phase
- Phase 1 (IND cleared, no reported enrollment)
- Time to market
- ABV-1519 has not yet reported Phase 1 trial initiation or enrollment. Assuming the program is active, a potential approval would be many years away, contingent on completing Phase 1, Phase 2, and Phase 3 trials, which typically take 5-10 years for oncology drugs. Given ABVC's financial distress, the timeline is highly uncertain.
- Why 2/10
- No hard, dated catalyst is scheduled for ABV-1519 in the next 12 months. The drug received FDA IND clearance in January 2023 but no clinical data, enrollment update, or regulatory milestone has been announced since. ABV-1519 is a minor, early-stage oncology program within a financially distressed micro-cap company, so its impact on ABVC's share price is minimal relative to the company's liquidity crisis and other pipeline assets.
ABV-1519 has no publicly announced clinical data or upcoming catalyst. The next meaningful event would be any update on patient enrollment or data from the Phase 1 study, but none has been scheduled or disclosed. The drug's fate is tied to ABVC's ability to survive as a going concern given its $11,294 cash position as of September 30, 2026.
Price Chart
Executive Summary
ABV-1519 is an early-stage oncology drug candidate from ABVC BioPharma (NASDAQ: ABVC) being developed for non-small cell lung cancer (NSCLC). The FDA cleared an Investigational New Drug (IND) application in January 2023, allowing the company to proceed with clinical studies, but no patient enrollment, dosing data, or results have been publicly reported since. ABV-1519 is part of a broader oncology pipeline that was included in a global licensing term sheet in April 2024. However, ABVC is a micro-cap company in severe financial distress with only $11,294 in cash as of September 30, 2026, a going concern warning, and zero product revenue. With no upcoming catalyst and no clinical progress visible, ABV-1519 is a stalled, early-stage program at a company fighting for survival.
How It Works
ABV-1519 is an investigational oncology drug candidate being developed for the treatment of non-small cell lung cancer (NSCLC). Its specific mechanism of action has not been publicly detailed by the company, but it is part of ABVC's oncology/hematology pipeline of botanical-derived or small-molecule therapeutics targeting solid tumors.
Trial Status
The FDA approved an IND for ABV-1519 in January 2023 for a clinical study in non-small cell lung cancer. No subsequent updates on patient enrollment, dosing, or results have been publicly disclosed. No ClinicalTrials.gov record was found for this specific drug candidate.
The Two-Sided Case
Upcoming Catalysts
- No scheduled catalysts identified. Any future catalyst would depend on ABVC providing a clinical update, initiating patient enrollment, or announcing a licensing/sub-licensing deal for ABV-1519.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ABVC BIOPHARMA, INC. 424B4 ABVC ·Originating report